Graduation Date

Summer 8-9-2019

Document Type


Degree Name

Master of Science (MS)


Pharmaceutical Sciences

First Advisor

Dong Wang


Ulcerative colitis is a chronic inflammatory bowel disease affecting the colon. More than 1 million Americans are affected, with the annual economic burden up to 14.9 billion in the United States. By far, ulcerative colitis still lacks the cure and the current treatment strategies are limited due to severe side effects and in-sufficient efficacy. The tofacitinib (Xeljanz) is the only approved oral medication by for adults with moderately-to-severely-active ulcerative colitis. But the related side effects and serious infections still have to be resolved. In the previous study in our lab, the researchers have successfully developed and characterized multiple hy-drophilic prodrug formulations (P-Dex-D and P-Tofa). We suppose these prodrugs can be orally administered with reduced systemic exposure according to their in vivo release profiles. In this study, these prodrugs are administered orally to dextran sulfate sodium induced ulcerative colitis murine model. The results demon-strated that these drugs can effectively ameliorate colitis and reduced side effects compared to their parent drugs.